Startseite>>Signaling Pathways>> Neuroscience>> Behavioral Neuroscience>>Ipidacrine

Ipidacrine (Synonyms: NIK-247)

Katalog-Nr.GC49299

2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]chinolin-9-amin ist eine pharmazeutisch aktive Verbindung, die ein Nootropikum ist, das als Cholinesterasehemmer wirkt und zur Behandlung der Alzheimer-Krankheit verwendet wird[1 ].

Products are for research use only. Not for human use. We do not sell to patients.

Ipidacrine Chemische Struktur

Cas No.: 62732-44-9

Größe Preis Lagerbestand Menge
500 mg
52,00 $
Auf Lager
1 g
70,00 $
Auf Lager
5 g
408,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ipidacrine is an inhibitor of acetylcholinesterase (AChE; IC50 = 270 nM).1 It induces long-term potentiation (LTP) in rat hippocampal slices, an effect that can be blocked by the muscarinic antagonists atropine or pirenzepine , when used at a concentration of 10 µM.2 Ipidacrine (0.03-1 mg/kg) prevents memory deficits induced by the anticholinergic agent scopolamine in the passive avoidance test in rats.2

1.Ogura, H., Kosasa, T., Kuriya, Y., et al.Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitroMethods Find. Exp. Clin. Pharmacol.22(8)609-613(2000) 2.Yoshida, S., and Suzuki, N.Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in ratsEur. J. Pharmacol.250(1)117-124(1993)

Bewertungen

Review for Ipidacrine

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ipidacrine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.